The DOI matches its Crossref record.
Treatment of downbeat nystagmus with 3,4-diaminopyridine: A placebo-controlled study
Abstract
BACKGROUND: Several drugs that primarily act on gamma-aminobutyrate or muscarinic receptors have been used to treat downbeat nystagmus (DBN) syndrome despite their having only moderate success and causing several side effects that limit their effectiveness. These drugs were tested under the assumption that DBN was caused by a disinhibition of a physiologic inhibitory cerebellar input on vestibular nuclei. OBJECTIVE: To evaluate the effects of a single dose of the potassium channel blocker 3,4-diaminopyridine (3,4-DAP), which is known to increase the excitability of Purkinje cells, on DBN in a prospective, placebo-controlled, double-blind study with a crossover design. METHODS: Seventeen patients with DBN due to cerebellar atrophy (5), infarction (3), Arnold-Chiari malformation (1), or unknown etiology (8) were included in the study (1 of 18 patients had to be excluded). Mean peak slow-phase velocity (PSPV) was measured before and 30 minutes after randomized ingestion of 20 mg of 3,4-DAP or placebo orally; at least 1 week later, the treatments were switched. RESULTS: 3,4-DAP reduced mean PSPV of DBN from 7.2 +/- 4.2 degrees /s (mean +/- SD) before treatment to 3.1 +/- 2.5 degrees/s 30 minutes after ingestion of the 3,4-DAP (p < 0.001, two-way analysis of variance). Placebo had no measurable effect. In 10 of 17 subjects, the mean PSPV decreased by >50% and in 12 of 17 by >40%. In parallel, the subjects had less oscillopsia and felt more stable while standing and walking. Nine of the subjects continued to take the drug with success. Except for transient minor perioral or digital paresthesia reported by three subjects and nausea and headache reported by one, no other side effects were observed. CONCLUSIONS: In this study, the authors demonstrated that a single dose of 3,4-DAP significantly improved DBN. In view of animal studies reporting that micromolar concentrations of 4-aminopyridine increased the excitability of Purkinje cells, it is suggested that the efficacy of 3,4-DAP may be due to an increase of the physiologic inhibitory influence of the vestibulocerebellum on the vestibular nuclei.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Primary episodic ataxias: diagnosis, pathogenesis and treatment
Jen, J. C., Graves, T. D., Hess, E. J., Hanna, M. G., Griggs, R. C., Baloh, R. W., & the CINCH investigators (2007) · Brain · doi:10.1093/brain/awm126 · Cited by 374
The neuro-ophthalmology of multiple sclerosis
Frohman, E. M., Frohman, T. C., Zee, D. S., McColl, R., & Galetta, S. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)00992-0 · Cited by 285
Cerebellum and Ocular Motor Control
Kheradmand, A., & Zee, D. S. (2011) · Frontiers in Neurology · doi:10.3389/fneur.2011.00053 · Cited by 269
Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine
Strupp, M., Kalla, R., Dichgans, M., Freilinger, T., Glasauer, S., & Brandt, T. (2004) · Neurology · doi:10.1212/01.wnl.0000125691.74109.53 · Cited by 253
Self-citationDownbeat nystagmus: Aetiology and comorbidity in 117 patients
Wagner, J. N., Glaser, M., Brandt, T., & Strupp, M. (2007) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.126284 · Cited by 195
Self-citation
Metadata
- Authors
- Strupp, M., Schüler, O., Krafczyk, S., Jahn, K., Schautzer, F., Büttner, U., & Brandt, T.
- Venue
- Neurology
- Published
- 2003-07-22
- Volume
- 61
- Issue
- 2
- Pages
- 165-170
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2023879879
- Cited by
- 244
- References
- 0
- FWCI
- 7.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of downbeat nystagmus with 3,4-diaminopyridine: A placebo-controlled study. https://app.cochat.ai/papers/10.1212/01.wnl.0000078893.41040.56
- The paper
- Strupp, M., Schüler, O., Krafczyk, S., Jahn, K., Schautzer, F., Büttner, U., & Brandt, T. (2003). Treatment of downbeat nystagmus with 3,4-diaminopyridine: A placebo-controlled study. Neurology. https://doi.org/10.1212/01.wnl.0000078893.41040.56
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.